The general objective of this proposed renewal for an ADRC at Columbia University is to foster innovative research on AD and related disorders, both locally in our extensive campus and more globally with other institutions and organizations. Informed by the funding opportunity announcement and influenced by recent advancements, a general theme of this renewal is better defining normal aging and the transition from normal aging to the earliest stages of AD. Since its inception 24 years ago, the ADRC at Columbia has established an elaborate infrastructure for research, fostered interdisciplinary collaborations, established a rich training environment, and promoted outreach and patient recruitment. At the same time the ADRC has become an active participant in a more global network comprised of other institutions, national consortia, and community organizations. During its latest cycle, the ADRC has attained most of its goals and its success is evidenced, for example, by the breadth of its scientific achievements and by its #1 ranking in the number of enrolled and active patients. In this proposed renewal, our ADRC will build off of these prior accomplishments moving forward, and will be motivated by two general goals. The first broad goal is to continue, as in previous cycles, to foster innovative research on AD and related disorders, while the second more specific goal is to support the theme of this cycle. These goals will be accomplished via a number of specific aims, which include: 1) Supporting and integrating the cores and other resources to facilitate research on AD and related disorders. 2) Fostering and expanding our multidisciplinary and multi-department local network at Columbia University with a focus on better understanding the relationship between aging and AD. 3) Fostering and expanding our participation in a global network outside of Columbia University, by playing active roles in national efforts and consortia that collect clinical, genetic, and neuroimaging data, as well as biospecimens. 4) Supporting the development of new techniques and methodologies, particularly in delineating the transition from aging to AD, and supporting the translation of thes findings into better diagnostic, prevention and treatment strategies. 5) Fostering and expanding education and outreach to patients, particularly individuals in the earliest stages of disease, and in the training of young and new investigators. The cores provide the structural backbone of our ADRC. As evidenced by the success of the cores during the previous cycle the same cores and their leaders will be part of this renewal, thereby assuring smooth continuity and the promise of future success. Besides the Administrative Core, these cores include: A Clinical Core led by Dr. Larry Honig; a Data Management and Statistical Core led by Dr. Howard Andrews; a Neuropathology Core led by Dr. Jean-Paul Vonsattel; a Human Genetics Core led by Dr. Richard Mayeux; and, an Outreach, Retention, and Education Core led by Dr. Karen Bell. The specific projects allow the ADRC to mobilize towards its scientific goals, and towards its expansionist goals of fostering new science, investigators, and careers. In this proposed renewal the ADRC will support three new projects, all led by new investigators. Dr. Adam Brickman will lead Project 1 entitled, Hippocampal circuitry and white matter abnormalities in aging and AD. Drs. Sandra Barral and Christiane Reitz will co-lead Project 2 entitled, Genetic variations linked to the aging hippocampus. Dr. John Crary will lead Project 3 entitled, Post- transcriptional regulation of tau in aging and AD.

Public Health Relevance

The general objective of the ADRC at Columbia University is to tackle the main barriers in the field of Alzheimer's disease and related disorders, which include early detection, prevention and intervention. In mobilizing towards this ambitious objective, the ADRC will expand its focus to include an investigation on normal aging and how aging translates to the earliest stages of disease. The ADRC will support an infrastructure for research, foster interdisciplinary collaborations, provide a rich training environment, and promote outreach and patient recruitment. More globally, the ADRC will participate in all national coordinating efforts and will work together with other institutions that collectively shar our objective.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Silverberg, Nina B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
Schools of Medicine
New York
United States
Zip Code
Qureshi, Yasir H; Patel, Vivek M; Berman, Diego E et al. (2018) An Alzheimer's Disease-Linked Loss-of-Function CLN5 Variant Impairs Cathepsin D Maturation, Consistent with a Retromer Trafficking Defect. Mol Cell Biol 38:
Reitz, Christiane (2018) Retromer Dysfunction and Neurodegenerative Disease. Curr Genomics 19:279-288
Tariciotti, Leonardo; Casadei, Matthew; Honig, Lawrence S et al. (2018) Clinical Experience with Cerebrospinal Fluid A?42, Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia. J Alzheimers Dis 65:1417-1425
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Masucci, Michael D; Lister, Amanda; Corcoran, Cheryl M et al. (2018) Motor Dysfunction as a Risk Factor for Conversion to Psychosis Independent of Medication Use in a Psychosis-Risk Cohort. J Nerv Ment Dis 206:356-361
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826

Showing the most recent 10 out of 640 publications